|
External Work Group Members |
|
|
Miriam Alter, PhD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Sanjeev Arora, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
Consultancy: Served on Advisory Board of Vertex Pharmaceuticals in 2009 Grants/Grants Pending: Grants from Vertex Pharmaceuticals, Roche/ Genentech, Gilead, Zyrnogenetics, Bristol Myers, Pharmasett, and Abbott paid to institution for clinical trials Lectures/ Speakers Bureaus: Scherring Corp., served on September Bureau for Roche Pharmaceuticals until mid-2009 |
|
Bruce Bacon, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Doug Campos-Outcalt, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Alfred DeMaria, Jr., MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Janet Durfee, MSN |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Yngve Falck-Ytter, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Colleen Flanigan, MS |
|
|
For the work under consideration: |
Support for Travel: CDC Foundation |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Marc Ghany, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Robert Gish, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
Board Membership: Hepahope Consultancy: Performed as a consultant to Abbott, Anadys Pharmaceuticals, Inc., Bayer AG, Bristol-Myers Squibb Company, Durect, Hepahope, Hoffman-LaRoche Ltd., Genentech, Gilead Sciences, GlaxoSmithKline, GlobeImmune, Human Genome Sciences, Merck, Metabasis Therapeutics, OSI/Astellas Parmasset, Schering-Plough Corporation, Three Rivers Pharma, VitalTherapies, and ZymoGenetics; payments directed to an SPF fund for research and education. Lectures/ Speakers Bureaus: Speakers bureau activities for Bayer, Bristol-Myers Squibb Company, F. Hoffman-LaRoche Ltd., Gilead Sciences, Inc., GlaxoSmithKline, Onyx, Merck/Schering-Plough Corporation, Three Rivers, Salix, SciClone Pharmaceuticals focused on HBV, HCV, and liver cancer, specifically epidemiology, diagnosis, and treatment, with additional program presentations for HBV and management of complications of cirrhosis; has a speakers contract to do promotional talks for BMS, Roche, Schering-Plough, Gilead Sciences, Bayer and Onyx; payments are directed to an SPF fund for research and education. Grants/ Grants Pending: Support from Bayer-Onyx, Bristol-Myers Squibb Company, Genentech/ F. Hoffman-LaRoche, Ltd., Gilead Sciences, Genentech, Pharmasset, Zymogenetics; payments directed to an institutional fund under contract to CPMC. Stock/ Stock Options: Major stock shareholder for Hepahope |
|
Fasiha Kanwal, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Emmett Keeffe, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
Consultancy: Vertex Travel/ Accommodations: Vertex |
|
Kathleen Koechlin, PhD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Cameron Lewis |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Jake Liang, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Robert Lubran, MPA |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Iris Mabry-Hernandez, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Katherine McGlynn, PhD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Barbara McGovern, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
Employment: Editor at UpToDate Other: Editor at Infectious Diseases Society of America |
|
Rachel McLean, MPH |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Michael Ninburg |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
Consultancy: Vertex, Abbott, Genentech, GlaxoSmithKline, Merck, Hoffman LaRoche, Tibotec, Boehringer Ingelheim Grants/ Grants Pending: Grants from Vertex, Merck, Genentech, Hoffman La Roche, Schering Plough, Gilead, Novartis, and Human Genome Sciences paid to institution Payment for the Development of Educational Presentations: Vertex, Hoffmann La Roche, and Schering Plough, paid to institution |
|
Phillip Reichert, MPH |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Vinod Rustgi, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
Consultancy: Merck, Vertex Grants/ Grants Pending: Grants from BMS, Gilead, Anadys, Boehringer-Ingelheim-Abbott paid to institution Lectures/ Speakers Bureaus: Merck, Vertex, Genentech, Gilead, Onyx |
|
Lorren Sandt |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
Consultancy: Abbott, for community advisory board and paid to institution Grants/ Grants Pending: Unrestricted educational grants from Vertex, Merck, and Genentech paid to institution; Conference grant from Gilead paid to institution Travel/ Accommodations: Money for travel from BMS, Vertex, Boehringer Ingelheim, Merck, Genentech/Roche and Tibotec for community advisory boards and paid to institution |
|
Gloria Searson |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Anne Spaulding, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
Consultancy: Georgia Correctional Healthcare; clinical consultant for hepatitis and HIV care Grants/ Grants Pending: Grant support from DHHS, CDC, HRSA, and indirectly from NIH paid to institution Lectures/ Speakers Bureaus: Hepatitis Foundation International, Albany Medical College |
|
Donna Sweet, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
Grants/ Grants Pending: Pfizer, BMS Pharmaceuticals Lectures/ Speakers Bureaus: Abbott, BMS, Boehringer Ingelheim, Tibotec, Gilead |
|
Andrew Talal, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
Board Membership: Merck & Co., Genentech/Roche, Boehringer Ingelheim, Pfizer, Bayer/ Onyx, Vertex Consultancy: Merck & Co., Genentech Grants/ Grants Pending: Merck & Co., Vertex, Boehringer-Ingelheim, and Genentech/Roche, Pfizer, Bayer/Onyx paid to institution Lectures/ Speakers Bureaus: Vertex and Genentech/ Roche Payment for Development of Educational Presentations: Merck & Co., Medscape |
|
Litjen Tan, PhD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Chris Taylor |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
Grants/ Grants Pending: Vertex, Gilead, OraSure, Merck & Co., Janssen, BMS paid to institution Travel/ Accommodations: Vertex, OraSure |
|
Lisa Townshend-Bulson, MSN |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
Expert Testimony: CDC Cooperative Agreement with ANTHC, paid to institution |
|
Tam Van |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Kathleen Whitaker, PhD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Richard Wild, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
John Wong, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
CDC Work Group Members |
|
|
Geoff Beckett, MPH |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Scott Holmberg, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Deborah Holtzman, PhD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Rebecca Morgan, MPH |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Dan Riedford, JD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Bryce Smith, PhD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Philip Spradling, MD |
|
|
For the work under cocnsideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
Chong-Gee Teo, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
|
John W. Ward, MD |
|
|
For the work under consideration: |
No financial conflict of interest reported |
|
Other relevant financial activities: |
No financial conflict of interest reported |
ShareCompartir
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Appendix A: Conflicts of Interest
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
